IL-1F10: A Potential Drug Target and Biomarker (G84639)

Target Name: IL1F10

NCBI ID: G84639

IL1F10

IL-1F10: A Potential Drug Target and Biomarker

Interleukin-38 (IL-1F10) is a cytokine that plays a crucial role in the regulation of immune responses and inflammation. The production and function of IL-1F10 have been implicated in a wide range of diseases, including autoimmune disorders, chronic obstructive pulmonary disease (COPD), and heart failure. As a result, targeting IL-1F10 has emerged as a promising strategy for the development of new therapeutic approaches.

IL-1F10 is a cytokine that is expressed in a variety of tissues and cells, including immune cells, epithelial cells, and tissues. It is a member of the IL-1 family of cytokines, which include IL-1, IL-2, and IL-12. The primary function of IL-1F10 is to regulate the production and response of immune cells, as well as modulate inflammation.

IL-1F10 has been shown to play a key role in the regulation of immune cell function and the production of antibodies. In addition, it has been implicated in the regulation of inflammation, including the production of pro-inflammatory cytokines. IL-1F10 has also been shown to be involved in the regulation of cell survival and the modulation of cell differentiation.

The production and function of IL-1F10 have been implicated in a wide range of diseases, including autoimmune disorders, chronic obstructive pulmonary disease (COPD), and heart failure. For example, studies have shown that IL-1F10 is involved in the development of autoimmune disorders, including rheumatoid arthritis (RA) and multiple sclerosis (MS). In addition, IL-1F10 has been shown to be involved in the regulation of COPD, including the production of pro-inflammatory cytokines and the modulation of lung function.

In addition to its role in disease, IL-1F10 has also been shown to have potential as a drug target. The production and function of IL-1F10 have been implicated in the regulation of a wide range of cellular processes, including cell survival, cell proliferation, and inflammation. As a result, targeting IL-1F10 has emerged as a promising strategy for the development of new therapeutic approaches.

One potential approach to targeting IL-1F10 is the use of small molecules that can inhibit its activity. These small molecules can be designed to specifically interact with IL-1F10 and prevent it from interacting with its receptors. By inhibiting IL-1F10 activity, small molecules can be used to treat a wide range of diseases, including autoimmune disorders, COPD, and heart failure.

Another potential approach to targeting IL-1F10 is the use of antibodies that can specifically recognize and target it. These antibodies can be used to treat a wide range of diseases, including autoimmune disorders, COPD, and heart failure. By using antibodies to target IL-1F10, researchers can prevent it from interacting with its receptors and effectively treat the associated diseases.

In conclusion, IL-1F10 is a potential drug target and biomarker that has the potential to revolutionize our understanding of a wide range of diseases. The production and function of IL-1F10 have been implicated in a wide range of diseases, including autoimmune disorders, COPD, and heart failure. As a result, targeting IL-1F10 with small molecules or antibodies has the potential to be a highly effective strategy for the development of new therapeutic approaches.

Protein Name: Interleukin 1 Family Member 10

Functions: Cytokine with immunomodulatory activity. Alone, does not induce cytokine production, but reduces IL22 and IL17A production by T-cells in response to heat-killed Candida albicans. Reduces IL36G-induced production of IL8 by peripheral blood mononuclear cells. Increases IL6 production by dendritic cells stimulated by bacterial lipopolysaccharides (LPS). Ligand for IL-36R/IL1RL2

The "IL1F10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL1F10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets